Modulating the Immune System
Home
About
Active Biotech in Brief
Board of Directors
Management
Business Concept
Corporate Governance
Corporate Governance Report 2017
Article of Association
Election Committee
General Meetings
Auditors
Partnerships
Career
Projects
Project Overview
ANYARA
Tasquinimod
SILC
Laquinimod
Paquinimod
Patents
Orphan Drug Designation
Investor
Investor
Financial Calendar
Financial Reports
Interim Reports
Annual Reports
Stock
Ownership
Official Documents
Rights Issue 2014
Rights Issue 2016
Rights Issue 2018
Media
Press Contact
Press Releases
Subscribe
News
Image Bank
Contact
Copyright © 2019 Active Biotech AB.
All Rights Reserved.
Design by
Clavis Communications
.
Media
Press Contact
Press Releases
News
Image Bank
News
Active Biotech Year-end report January – December 2018
February 14, 2019
Active Biotech’s partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
February 11, 2019
Active Biotech has received an indicative bid for the property in Lund – the Board is positive
February 1, 2019
Active Biotech provides updated information about the company’s financial position
December 10, 2018
Interim report January – September 2018
November 15, 2018
New data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at the scientific conference HSG 2018
November 8, 2018
<\span>
Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington’s disease will be presented at “European Huntington’s Disease Network (EHDN) plenary meeting 2018”
September 13, 2018
Active Biotech regains global rights to development and commercialization of laquinimod
September 5, 2018
Active Biotech AB – Interim Report January – June 2018
August 9, 2018
Active Biotech provides update on laquinimod in Huntington’s disease
July 31, 2018
This site uses cookies.
Okay, thanks